CI&T (NYSE:CINT) & Black Titan (NASDAQ:BTTC) Critical Comparison

Black Titan (NASDAQ:BTTC) and CI&T (NYSE:CINT) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Black Titan and CI&T, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
CI&T	2	2	7	0	2.45

CI&T has a consensus price target of $6.08, suggesting a potential upside of 101.05%. Given CI&T’s stronger consensus rating and higher possible upside, analysts clearly believe CI&T is more favorable than Black Titan.

Insider & Institutional Ownership

92.4% of CI&T shares are owned by institutional investors. 53.7% of Black Titan shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Black Titan and CI&T”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Titan	$2.18 million	1.80	-$4.71 million	($2.95)	-0.12
CI&T	$489.65 million	0.83	$40.62 million	$0.29	10.42

CI&T has higher revenue and earnings than Black Titan. Black Titan is trading at a lower price-to-earnings ratio than CI&T, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Black Titan has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, CI&T has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Profitability

This table compares Black Titan and CI&T’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	N/A	N/A
CI&T	6.79%	11.69%	6.51%

Summary

CI&T beats Black Titan on 11 of the 14 factors compared between the two stocks.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.

About CI&T

CI&T, Inc. provides strategy, design and software engineering services to enable digital transformation. The firm’s solutions and services include Digital Strategy, Customer-Centric Design and Top-of-the-Line Software Engineering. The company was founded by Cesar Nivaldo Gon, Bruno Guiçardi Neto and Fernando Matt Borges Martins on June 7, 2021 and is headquartered in Sao Paulo, Brazil.